References
- Cortes JE, Kantaqian H. Chronic leuke-mias. In: Pazdur R, Coia LD, Hoskins WJ, et al, eds. Cancer management: a multidisciplinary approach. 2d ed. Huntington, NY: Publisher Research Management, Ine, 1998: 306–15
- Cortes JE, Talpaz M, Kantarjian H. Chronic myelogenous leukemia: a review. Am J Med 1996; 100(5): 555–70
- Cortes J, Kantarjian HM, Giralt S, et al. Natural history and staging of chronic myelogenous leukaemia. Baillieres Clin Haematol 1997; 10(2): 277–90
- Hughes TP, Goldman JM. Chronic myeloid leukemia. In: Hoffman R, Benz EJ, Shattil SJ, et al, eds. Hematology: basic principles and practice. 2d ed. New York: Churchill Livingstone, 1995: 1142–59
- Goldman J. Chronic myeloid leukaemia. BMJ (Clin Res Ed) 1997; 314: 657–60
- Goldman JM. Treatment of chronic myeloid leukaemia: some topical questions. Baillieres Clin Haematol 1997; 10(2): 405–21
- Fischer DS, Knobf MT, Durivage HJ. The cancer chemotherapy handbook. 5th ed. St Louis: Mosby, 1997: 132–3
- O'Brien S, Kantarjian H, Keating M, et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 1995; 86(9): 3322–6
- Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994; 330(12): 820–5
- Kantarjian HM, Smith TL, O'Brien S, et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med 1995; 122(4): 254–61
- Hehlmann R. Chronic myelogenous leukemia: does interferon alpha prolong life? Leukemia 1996; 10(2): 193–6
- Carella AM, Frassoni F, Melo J, et al. New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia. Haematologica 1997; 82(4): 478–95
- Guilhot F, Chastang C, Michallet M, et al, for the French Chronic Myeloid Leukemia Study Group. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 1997; 337(4): 223–9
- Kantarjian H, O'Brien S, Keating MM, et al. Interferon alpha (INF-a) and low-dose cytosine arabinoside (ARA-C) therapy in Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML). (Abstr) Proc Assoc Am Soc Clin Oncol 1997; 16: 13a
- Guilhot F, Chastang C, Guerci A, et al. Interferon alpha2b (IFN) and cytarabine (Ara-C) increase survival and cytogenetic response in chronic myeloid leukemia (CML): results of a randomized trial. (Abstr) Blood 1996; 88(Suppl): 141a
- Gajewski J, Champlin R. Bone marrow transplantation from alternate donors. In: Burt RK, Deeg HJ, Lothian ST, eds. On call in… bone marrow transplantation. Austin: RG Landes, 1996: 27
- Hansen JA, Gooley TA, Martin PJ, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998; 338(14): 962–8
- Goldman JM. Chronic myeloid leukemia: new strategies for cure. In: McArthur JR, Schechter GP, Piatt OS, et al, eds. Washington, DC: American Society of Hematology Educational Program Book, 1997: 1–7
- Forman SJ. Bone marrow transplantation. In: Pazdur et al, eds, 1 p 633
- Mackinnon S. Donor leukocyte infusions. Baillieres Clin Haematol 1997; 10(2): 357–67